Chase Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Chase Therapeutics General Information

Description

Operator of a pharmaceutical company intended to develop drugs for the treatment of brain disease. The company's novel compounds employ approaches to both symptomatic relief and disease modification, enabling doctors to treat those affected by central nervous system disorders and improve their quality of life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1825 K Street Northwest
  • Suite 510
  • Washington, DC 20006
  • United States
+1 (202)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 1825 K Street Northwest
  • Suite 510
  • Washington, DC 20006
  • United States
+1 (202)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chase Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 16-Dec-2021 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A3) 29-Oct-2019 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A2) 28-Aug-2018 $4M $5.3M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A1) 21-Nov-2017 $1.3M $1.3M Completed Clinical Trials - Phase 1
To view Chase Therapeutics’s complete valuation and funding history, request access »

Chase Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A4
Series A3
Series A2 2,000,000 $0.000100 $0.1 $2 $2 1x $2 11.12%
Series A1 1,300,000 $0.000100 $0.05 $1 $1 1x $1 7.23%
To view Chase Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Chase Therapeutics Patents

Chase Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025145022-A1 Compositions and methods for treating anhedonia Inactive 28-Dec-2023
AU-2022293855-A1 Diagnostic indices for neurodegenerative conditions Inactive 15-Jun-2021
CA-3222315-A1 Diagnostic indices for neurodegenerative conditions Pending 15-Jun-2021
EP-4356143-A1 Diagnostic indices for neurodegenerative conditions Inactive 15-Jun-2021
EP-4356143-A4 Diagnostic indices for neurodegenerative conditions Inactive 15-Jun-2021 G16H50/20
To view Chase Therapeutics’s complete patent history, request access »

Chase Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
ChinaLink Capital PE/Buyout Minority
ChinaLink ESG T Corporate Venture Capital Minority
To view Chase Therapeutics’s complete investors history, request access »

Chase Therapeutics FAQs

  • When was Chase Therapeutics founded?

    Chase Therapeutics was founded in 2017.

  • Where is Chase Therapeutics headquartered?

    Chase Therapeutics is headquartered in Washington, DC.

  • What industry is Chase Therapeutics in?

    Chase Therapeutics’s primary industry is Drug Discovery.

  • Is Chase Therapeutics a private or public company?

    Chase Therapeutics is a Private company.

  • What is Chase Therapeutics’s current revenue?

    The current revenue for Chase Therapeutics is .

  • How much funding has Chase Therapeutics raised over time?

    Chase Therapeutics has raised $45.3M.

  • Who are Chase Therapeutics’s investors?

    ChinaLink Capital and ChinaLink ESG T have invested in Chase Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process